(Tecentriq), a fully humanized, monoclonal anti-programmed cell death ligand-1 (PD-L1) antibody, is the first immune checkpoint inhibitor to be approved, in combination with carboplatin and etoposide, for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). App...
Intensive chemotherapy for extensive-stage small-cell lung cancer (SCLC)INTERLEUKIN-2BCNUCHEMOIMMUNOTHERAPYL1210The replication cycle of human immunodeficiency virus type 1 (HIV-1) consists of four distinct stages, each of which can be targeted for specific antiviral chemotherapy. The stages are (1)...
Find out about TECENTRIQ® (atezolizumab) for the treatment of extensive-stage small cell lung cancer (ES-SCLC). See full safety for more information.
Small cell lung cancer (SCLC) is a highly malignant and poor-prognosis cancer, with most cases diagnosed at the extensive stage (ES). Amidst a landscape marked by limited progress in treatment modalities for ES-SCLC over the past few decades, the integration of immune checkpoint inhibitors (ICI...
Find out about TECENTRIQ® (atezolizumab) for the treatment of extensive-stage small cell lung cancer (ES-SCLC). See full safety for more information.
Notably, recent progress in the understanding of the molecular biology of SCLC might bring possibilities toward molecularly informed therapeutic strategies for patients with SCLC, which could have a significant impact for improving outcomes in this disease. Here, we review current treatment options and ...
• In patients with limited-stage SCLC who have a good response to initial therapy, PCI decreases brain metastases and increases overall survival (category 1).22,23In patients with extensive-stage SCLC that has responded to systemic therapy, PCI decreases brain metastases. However, while a rando...
Durvalumab (IMFINZI), a fully human monoclonal antibody against programmed cell death-ligand 1 (PD-L1), is approved for use in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). In the ...
In the dose-optimization part of IDeate-Lung01, two doses of I-DXd (8 mg/kg and 12 mg/kg intravenously every 3 weeks) were evaluated in patients with extensive-stage SCLC previously treated with one to three prior lines. The primary endpoint was objective response rate by blinded ...
In their updated guidelines for patients with small cell lung cancer (SCLC), ASCO has recommended the CDK4/6 inhibitor trilaciclib as a myeloid supportive agent for patients with untreated or previously treated extensive-stage SCLC who are receivin...